In 2017, the Epi proLung® blood-based version for the lung cancer test received the CE-IVD mark, which is based on a combination of the methylation analyses of SHOX2 and PTGER4 (the prostaglandin E receptor 4 gene). Here, PTGER4 is linked to lung carcinoma.